Search Results
Jan 20, 2026, 04:17 ET Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational Services
that accelerate project timelines and reduce development risks.Services are applied across molecular diagnostics, vaccine development, gene editing, gene therapy, agricultural biotechnology, and antibody drug discovery, helping clients translate scientific discoveries into practical solutions.Quality
More news about: Beijing Tsingke Biotech Co., Ltd.
Jan 19, 2026, 11:44 ET Alcami Acquires RTP Facility to Further Expand Biologic Capabilities
will enhance Alcami's ability to support a broad range of complex therapeutics, including biologics, peptides, proteins, oligonucleotides, and cell and gene therapy drug substances."This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in
More news about: Alcami
Jan 19, 2026, 06:19 ET MGI Tech empowers the University of Lisbon to study impact of Saharan dust on Portuguese agriculture -Vineyards as Key Case Study
service facilities globally.MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech Co., Ltd.
Jan 17, 2026, 11:48 ET Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Jan 16, 2026, 16:40 ET Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Muscular DystrophyDuchenne Muscular Dystrophy is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy.
More news about: Atossa Therapeutics Inc
Jan 16, 2026, 09:09 ET Ouroboros Announces Leading $60M Series A Investment in Cytotheryx to Advance Cell Therapy Platform for Liver Disease
a significant clinical need with limited existing solutions."The financing validates continued investor interest in next generation cell and gene therapy platforms despite a challenging biotech investment climate. Cytotheryx's technology portfolio includes a bio-incubator platform to produce liver
More news about: Ouroboros
Jan 15, 2026, 09:00 ET Oxford-Harrington Rare Disease Centre Invites Proposals for 2026 Award
metAccess to core facilities and infrastructure including oligonucleotide synthesis and screening, small molecule and protein platforms, cell and gene therapy facilitiesOpportunity to compete for acceleration funds up to USD$300,000 / £250,000Opportunity to qualify for investment
More news about: Harrington Discovery Institute
Jan 15, 2026, 09:00 ET Oxford-Harrington Rare Disease Centre Invites Proposals for 2026 Award
metAccess to core facilities and infrastructure including oligonucleotide synthesis and screening, small molecule and protein platforms, cell and gene therapy facilitiesOpportunity to compete for acceleration funds up to USD$300,000 / £250,000Opportunity to qualify for investment
More news about: Harrington Discovery Institute
Jan 15, 2026, 09:00 ET Placental Scientist Wins March of Dimes Agnes Higgins Award
translational, advancing the field's grasp on the complexities of fetal growth and inspiring various mTOR-related therapeutics currently under development, like gene targeting, to put at-risk babies on a better trajectory," said March of Dimes Chief Scientific Advisor Dr. Emre Seli. "His contributions have been crucial,
More news about: March of Dimes
Jan 14, 2026, 23:08 ET Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy
More news about: Belief BioMed
Jan 14, 2026, 12:30 ET DANA FOUNDATION APPOINTS KELSEY MARTIN TO BOARD OF DIRECTORS
biology of long-term memory with a focus on how experience alters connectivity between neurons. Her laboratory pioneered studies on the regulation of gene expression within neurons during long-term memory formation, highlighting a critical role for signaling between the synapse and nucleus and for local
More news about: Dana Foundation
Jan 14, 2026, 11:33 ET SeaWorld Unveils a Coast-to-Coast Live Music Series for 2026
throughout the season. The national lineup includes acts such as Flo Rida, Boyz II Men, The Beach Boys, Fitz and the Tantrums, Bow Wow, Soulja Boy, Gene Simmons, Ying Yang Twins, Uncle Kracker, and the Pop 2000 Tour featuring Chris Kirkpatrick of *NSYNC, O-Town, Ryan Cabrera, and LFO,
More news about: United Parks and Resorts Inc.
Jan 14, 2026, 08:03 ET iotaMotion Receives FDA Clearance for Expanded Pediatric Use of iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System
cochlea and preserve its structure and function. This is especially important for children who may benefit from emerging therapeutic advances, including gene-based and regenerative hearing technologies, which will likely depend on atraumatic, cochlear implant array placement early in life."About
More news about: iotaMotion, Inc.
Jan 14, 2026, 08:03 ET iotaMotion Receives FDA Clearance for Expanded Pediatric Use of iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System
cochlea and preserve its structure and function. This is especially important for children who may benefit from emerging therapeutic advances, including gene-based and regenerative hearing technologies, which will likely depend on atraumatic, cochlear implant array placement early in life."About
More news about: iotaMotion, Inc.
Jan 13, 2026, 09:09 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific.To
More news about: EspeRare Foundation
Jan 13, 2026, 09:00 ET 2025 VETTY Awards® Winners Exemplify Marketing Excellence in Animal Health Care Worldwide
everywhere."Each year, the VETTY Awards® honors the top marketing champions in animal health care, and this year was no exception," said NAVC CEO Gene O'Neill. "Like athletic champions who separate themselves by fractions of a second, these winners excelled where it mattered most — precision, creativity,
More news about: North American Veterinary Community (NAVC)
Jan 13, 2026, 08:47 ET Korea University Study Mimics Heart Mechanics in Organoids Using Three-Dimensional Magnetic Torque
physiological cardiac mechanics. Organoid maturation and vascularization were evaluated using molecular, structural, and functional analyses, including gene and protein expression profiling, immunofluorescence imaging, beating and calcium transient measurements, and transcriptomic analysis, enabling systematic
More news about: Korea University
Jan 13, 2026, 08:44 ET Applied Cells and Immuneel Therapeutics Announce Strategic Collaboration to Advance Truly Affordable CAR-T Cell Therapies in India and Globally
About Immuneel Therapeutics Immuneel Therapeutics is a clinical-stage biotechnology company developing affordable, best-in-class cell and gene therapies, with a focus on CAR-T therapies for cancer patients in India and emerging markets. Immuneel is committed to building a sustainable end-to-end
More news about: Applied Cells
Jan 13, 2026, 08:01 ET Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
most."Menkes disease is a rare X-linked recessive pediatric disease caused by mutations of the copper transporter ATP7A encoded by the ATP7A gene. Patients with Menkes disease are born with the inability to absorb dietary copper and subsequently have impaired copper transport across the blood-brain
More news about: Sentynl Therapeutics
Jan 13, 2026, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten)
care."About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Jan 13, 2026, 08:00 ET Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
evaluate in Phase 3.Reported initial results from the FOX Phase 2 placebo-controlled trial in participants with Duchenne previously treated with gene therapy that also supported that sevasemten 10 mg has the potential to reduce the rate of functional decline.EDG-7500 Announced
More news about: Edgewise Therapeutics
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1 protein, RAG-17
More news about: Ractigen Therapeutics
Jan 13, 2026, 03:00 ET n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares
ces patients grâce au développement de traitements individualisés à base d'ASO — de courts brins d'ADN modifié ciblant précisément les transcrits d'un gène défectueux afin de corriger l'anomalie. Ces traitements expérimentaux présentent l'avantage de pouvoir être développés rapidement, à moindre coût et
More news about: EspeRare Foundation
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific.
More news about: EspeRare Foundation
Jan 12, 2026, 12:49 ET PEGASUS WORLD CUP CELEBRATES 10 YEARS AS HORSE RACING'S HOTTEST EVENT
racing industry, fans, and celebrities, including Camila Cabello, Alix Earle, Rick Ross, Anuel AA, Jennifer Lopez, Gene Simmons, Lenny Kravitz, Pharrell Williams, Usher, Vanessa Hudgens, Vin Diesel, Maluma and Venus Williams,
More news about: Pegasus World Cup 2026